guest ::
| Home > Publications database > Generation of CAR-T cells using lentiviral vectors > print |
| 001 | 177487 | ||
| 005 | 20240229133741.0 | ||
| 037 | _ | _ | |a DKFZ-2021-02574 |
| 100 | 1 | _ | |a Mansour, P. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Generation of CAR-T cells using lentiviral vectors |
| 260 | _ | _ | |a United States |c 2021 |b Academic Press Inc. |
| 295 | 1 | 0 | |a Methods in Cell Biology |
| 300 | _ | _ | |a - |
| 336 | 7 | _ | |a BOOK_CHAPTER |2 ORCID |
| 336 | 7 | _ | |a Book Section |0 7 |2 EndNote |
| 336 | 7 | _ | |a bookPart |2 DRIVER |
| 336 | 7 | _ | |a INBOOK |2 BibTeX |
| 336 | 7 | _ | |a Output Types/Book chapter |2 DataCite |
| 336 | 7 | _ | |a Contribution to a book |b contb |m contb |0 PUB:(DE-HGF)7 |s 1637231604_29975 |2 PUB:(DE-HGF) |
| 520 | _ | _ | |a Cancer immunotherapy is nowadays largely focused on the development of therapeutic antibodies and chimeric antigen receptors (CARs). Two CARs targeting CD19 have been approved recently for the treatment of some hematological malignancies. This demonstrates the capability of engineered CAR T cells in generating effective tumor responses. Furthermore, several hundred ongoing clinical trials are exploring the feasibility of CAR-based approaches to target tumor-associated antigens in solid tumors. However, there still remain significant challenges and limitations in the design and production of CAR-modified T cells that need to be addressed, such as more effective transduction methods, expression and exhaustion issues, reliable in vitro and in vivo characterization methods, etc. Here we describe current techniques for generating CAR T cells using lentiviral vectors as well as detailed protocols for their functional characterization.https://reader.elsevier.com/reader/sd/pii/S0091679X21000844?token=19B8578AB0A842C9E0A423517A3E8821C298512484E57C501C77B440E558856281E370B178DDAB9F208EBEE22E875043&originRegion=eu-west-1&originCreation=20211118072303 |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 700 | 1 | _ | |a Quiros Fernandez, Isaac |0 P:(DE-He78)987b26d1b6cb44a440dac6d4342fc8d2 |b 1 |u dkfz |
| 700 | 1 | _ | |a Fakhr, Elham |0 P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d |b 2 |u dkfz |
| 700 | 1 | _ | |a Cid-Arregui, Angel |0 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |b 3 |u dkfz |
| 909 | C | O | |o oai:inrepo02.dkfz.de:177487 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)987b26d1b6cb44a440dac6d4342fc8d2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 920 | 1 | _ | |0 I:(DE-He78)D122-20160331 |k D122 |l D122 AG Gezielte Tumorvakzine |x 0 |
| 980 | _ | _ | |a contb |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D122-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|